Global Clinical Diagnostics Market - 2023-2030

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,350	195 Pages	DataM Intelligence 4Market Research LLP	July, 2023	DTAM18086865

Best Price Guarantee
Price	from $4,350
Length	195 Pages
Publisher	DataM Intelligence 4Market Research LLP
Published Date	July, 2023
SKU	DTAM18086865

Global Clinical Diagnostics Market - 2023-2030

The global clinical diagnostics market reached US$ 73.2 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 110.0 billion by 2030. The global clinical diagnostics market is expected to exhibit a CAGR of 5.3% during the forecast period (2023-2030).

In molecular diagnostic methods, genetic material (DNA or RNA) is analyzed to find genetic variants, mutations, or particular biomarkers linked to diseases. The commonly used molecular technique known as polymerase chain reaction (PCR) amplifies and detects particular DNA sequences. Genetic testing, infectious disease testing, cancer profiling, and the detection of genetic diseases all use molecular diagnostics.

Market Dynamics
Active Major Players are Boosting the Global Clinical Diagnostics Market Growth During the Forecast Period

In February 2023, In order to further boost its research and innovation efforts, Roche stated that it had increased its partnership with Janssen Biotech Inc. to develop companion diagnostics for targeted treatments.

With the new, enlarged partnership, Roche and Janssen will have more options to work together on companion diagnostics projects in the area of precision medicine, including immunohistochemistry (IHC), digital pathology, next-generation sequencing, polymerase chain reaction, and immunoassays.

Technological Advancements Provide Global Clinical Diagnostics Market Growth Opportunities

In March 2023, In an effort to standardize the locally developed Tata MD CHECK and reduce the rate of new infections, Tata Medical and Diagnostics (Tata MD), a new healthcare company from the Tata family, has partnered with Chennai-based Anderson Diagnostics & Labs (ADL).

The ""Made-in-India"" Tata MD CHECK diagnostic kit can now be scaled up quickly due to the collaboration with ADL's clinical experts. ADL has already successfully completed over 10,000 COVID tests using this new, DGCA-approved, novel diagnostic solution based on the Feluda CRISPR Platform. ""After testing and validating more than 10,000 samples, we believe this technology to be both cutting edge and on par with the best in the world.

COVID-19 Impact Analysis
The COVID-19 pandemic has had a significant impact on the clinical diagnostics market. Clinical diagnostics research and development have been sparked by the COVID-19 pandemic. New diagnostic assays, technologies, and platforms made specifically for the detection of COVID-19 have developed quickly. These developments have aided in the fight against the pandemic and have generated new ideas and information that will help the clinical diagnostics industry as a whole.

Russia-Ukraine Conflict Analysis
The impact of the Russia-Ukraine war on the clinical diagnostics market is complex and multifaceted. Due to a lack of infrastructure, resources, and knowledge, access to new diagnostic technology may be difficult in conflict-affected areas. The use and accessibility of cutting-edge diagnostic techniques, including molecular diagnostics or imaging technology, may be constrained, which could have an impact on the accuracy and thoroughness of diagnostic services.

Segment Analysis
The global clinical diagnostics market is segmented based on test, product, end-user, and region.

The Lipid Panel Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period

The lipid panel segment accounted for the highest market stake accounting for approximately 32.3% of the clinical diagnostics market in 2022. The lipid panel measures different lipids (fats) and the characteristics that go along with them in the bloodstream. It offers significant details on a person's lipid profile and cholesterol levels, which are essential markers of cardiovascular health.

Low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol are both measured as well as the overall amount of cholesterol in the blood. Healthcare providers can determine a patient's risk for cardiovascular disease based on the findings of a lipid panel test and offer medication, lifestyle changes, or other therapies as necessary.

Geographical Analysis
Asia Pacific is Expected to hold Around 25.7% Share of this Market due to Increasing Collaborations and Partnerships Among the Key Players, and Advancement in Clinical Diagnostics

Asia Pacific is expected to hold around 25.7% share of this market. For instance, in May 2023, a high-end diagnostic solutions provider called Core Diagnostics, with its headquarters in Gurugram, announced the opening of a new satellite facility in East Delhi's Hargobind Enclave. With this strategic growth, the company hopes to increase its testing capabilities and give patients and healthcare professionals better access to high-quality diagnostic services.

The satellite lab is a crucial component of Core Diagnostics' strategic expansion plan, which aims to increase the company's testing capacity and satisfy the increasing demand for quality and timely diagnostic services. By bringing superior diagnostic options closer to healthcare professionals and patients, they are able to give them the precise information they need to make prompt medical decisions.

Competitive Landscape
The major global players in the market include Abbott Laboratories, Becton, Dickinson and Company, BioMerieux, Bio-Rad Laboratories Inc., Danaher Corporation, Siemens AG, Hologic Inc., Qiagen NV, F. Hoffmann-La Roche AG, Thermo Fisher Scientific among others.

Why Purchase the Report?
• To visualize the global clinical diagnostics market segmentation based on the test, product, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of clinical diagnostics market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global clinical diagnostics market report would provide approximately 61 tables, 61 figures, and 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

1. Methodology and Scope: 1.1. Research Methodology; 1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary: 3.1. Snippet by Test; 3.2. Snippet by Product; 3.3. Snippet by End-user; 3.4. Snippet by Region
4. Dynamics: 4.1. Impacting Factors; 4.1.1. Drivers; 4.1.1.1. Rising burden of disease; 4.1.2. Restraints; 4.1.2.1. Stringent regulatory requirements; 4.1.3. Opportunity; 4.1.3.1. Technological advancements; 4.1.4. Impact Analysis
5. Industry Analysis: 5.1. Porter's 5 Forces Analysis; 5.2. Supply Chain Analysis; 5.3. Unmet Needs; 5.4. Regulatory Analysis
6. COVID-19 Analysis: 6.1. Analysis of COVID-19; 6.1.1. Scenario Before COVID-19; 6.1.2. Scenario During COVID-19; 6.1.3. Scenario Post COVID-19; 6.2. Pricing Dynamics Amid COVID-19; 6.3. Demand-Supply Spectrum; 6.4. Government Initiatives Related to the Market During the Pandemic; 6.5. Manufacturers’ Strategic Initiatives; 6.6. Conclusion
7. Russia-Ukraine War Analysis
8. Artificial Intelligence Analysis
9. By Test: 9.1. Introduction; 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test; 9.1.2. Market Attractiveness Index, By Test; 9.2. Lipid Panel*; 9.2.1. Introduction; 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 9.3. Liver Panel; 9.4. Renal Panel; 9.5. Complete Blood Count; 9.6. Electrolyte Testing; 9.7. Infectious Disease Testing; 9.8. Other Tests
10. By Product: 10.1. Introduction; 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product; 10.1.2. Market Attractiveness Index, By Product; 10.2. Instruments*; 10.2.1. Introduction; 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 10.3. Reagents; 10.4. Others
11. By End-user: 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user; 11.1.2. Market Attractiveness Index, By End-user; 11.2. Hospital Laboratory*; 11.2.1. Introduction; 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 11.3. Diagnostic Laboratory; 11.4. Point-of-care Testing; 11.5. Others
12. By Region: 12.1. Introduction; 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region; 12.1.2. Market Attractiveness Index, By Region; 12.2. North America; 12.2.1. Introduction; 12.2.2. Key Region-Specific Dynamics; 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test; 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product; 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user; 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 12.2.6.1. U.S.; 12.2.6.2. Canada; 12.2.6.3. Mexico; 12.3. Europe; 12.3.1. Introduction; 12.3.2. Key Region-Specific Dynamics; 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test; 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product; 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user; 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 12.3.6.1. Germany; 12.3.6.2. U.K.; 12.3.6.3. France; 12.3.6.4. Italy; 12.3.6.5. Spain; 12.3.6.6. Rest of Europe; 12.4. South America; 12.4.1. Introduction; 12.4.2. Key Region-Specific Dynamics; 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test; 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product; 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user; 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 12.4.6.1. Brazil; 12.4.6.2. Argentina; 12.4.6.3. Rest of South America; 12.5. Asia-Pacific; 12.5.1. Introduction; 12.5.2. Key Region-Specific Dynamics; 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test; 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product; 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user; 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 12.5.6.1. China; 12.5.6.2. India; 12.5.6.3. Japan; 12.5.6.4. Australia; 12.5.6.5. Rest of Asia-Pacific; 12.6. Middle East and Africa; 12.6.1. Introduction; 12.6.2. Key Region-Specific Dynamics; 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test; 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product; 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
13. Competitive Landscape: 13.1. Competitive Scenario; 13.2. Product Benchmarking; 13.3. Company Share Analysis; 13.4. Key Developments and Strategies
14. Company Profiles: 14.1. Abbott Laboratories*; 14.1.1. Company Overview; 14.1.2. Product Portfolio and Description; 14.1.3. Financial Overview; 14.1.4. Key Developments; 14.2. Becton, Dickinson and Company; 14.3. BioMerieux; 14.4. Bio-Rad Laboratories Inc.; 14.5. Danaher Corporation; 14.6. Siemens AG; 14.7. Hologic Inc.; 14.8. Qiagen NV; 14.9. F. Hoffmann-La Roche AG; 14.10. Thermo Fisher Scientific; LIST NOT EXHAUSTIVE
15. Appendix: 15.1. About Us and Services; 15.2. Contact Us